Biover­a­tiv climbs on board Bi­cy­cle's pep­tide plat­form in dis­cov­ery deal; Iron­wood CFO jumps ship, joins Ver­tex

⇨ Bio­gen spin­out Biover­a­tiv is col­lab­o­rat­ing with Bi­cy­cle Ther­a­peu­tics on new he­mo­phil­ia and sick­le cell dis­ease pep­tide ther­a­pies. The deal comes with $10 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER